Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, on June 29, 2026. The report covers events occurring between June 25, 2026, and June 29, 2026, primarily concerning executive appointments and Board of Directors changes.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial disclosure relates to executive compensation arrangements:
- Interim CFO Compensation: John P. Sharp will be billed at a flat rate of $455 per hour for up to 24 hours per week under a Master Services Agreement with Lohman & Associates, Inc.
- Director Compensation: Non-employee directors receive an annual fee of $35,000 for the fiscal year ending December 31, 2026, plus equity awards.
Material Changes
The following material changes were reported:
- Appointment of Interim CFO: John P. Sharp was appointed Interim Chief Financial Officer effective June 25, 2026, replacing Quang X. Pham in that interim role. The Company is conducting a search for a permanent CFO.
- Board Resignation: Steven Zelenkofske, a Class III director, resigned effective June 30, 2026. The resignation was not due to any disagreement with the Company.
- Board Realignment: To maintain three equal classes of directors, Dr. Glynn Wilson resigned as a Class I director and was immediately reappointed as a Class III director, serving until the 2028 annual meeting. He was also reappointed to the Audit and Nominating Committees and appointed to the Compensation Committee.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the Company's business outlook or contingencies. The appointment of an interim CFO indicates an ongoing search for a permanent executive to lead financial operations.
Key Facts for Investor Verification
- Verify the timeline for the search and appointment of a permanent Chief Financial Officer.
- Confirm the impact of the Board realignment on committee composition and quorum.
- Review the attached Master Services Agreement (Exhibit 10.1) and Statement of Work (Exhibit 10.2) for full terms of the Interim CFO engagement.
- Monitor future filings for the next quarterly report to assess financial liquidity and cash burn rates, as this 8-K contains no financial statements.